PPARG and breast neoplasm: More interestingly, synthetic and natural PPARγ agonists significantly reduced the production of the cytokine IL1Ra, simultaneously attenuating both M1 and M2 macrophage phenotypes, which are known to promote a pro-tumorigenic milieu in the breast tumor microenvironment.